nach oben

Neurotherapeutics

Erschienen in:

01.07.2011 | Review

Blood Biomarkers of Ischemic Stroke

verfasst von: Glen C. Jickling, Frank R. Sharp

Erschienen in: Neurotherapeutics | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

This review provides a summary of the protein and RNA biomarkers that have been studied for the diagnosis and assessment of ischemic stroke. Many of the biomarkers identified relate to the pathophysiology of ischemic stroke, including ischemia of CNS tissue, acute thrombosis and inflammatory response. These biomarkers are summarized by their intended clinical application in ischemic stroke including diagnosis, prediction of stroke severity and outcome, and stratification of patients for stroke therapy. Among the biomarkers discussed are recent whole genome studies using RNA expression profiles to diagnose ischemic stroke and stroke etiology. Though many candidate blood based biomarkers for ischemic stroke have been identified, none are currently used in clinical practice. With further well designed study and careful validation, the development of blood biomarkers to improve the care of patients with ischemic stroke may be achieved.

Nur mit Berechtigung zugänglich

Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O’Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics--2009 update. A report from the american heart association statistics committee and stroke statistics subcommittee. Circulation. 2008

Saenger AK, Christenson RH. Stroke biomarkers: Progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010;56:21–33PubMedCrossRef

Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Invited article: Searching for oracles? Blood biomarkers in acute stroke. Neurology. 2009;73:393–399PubMedCrossRef

Jensen MB, Chacon MR, Sattin JA, Levine RL, Vemuganti R. Potential biomarkers for the diagnosis of stroke. Expert Rev Cardiovasc Ther. 2009;7:389–393PubMedCrossRef

Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: A systematic review. Stroke. 2009;40:e380–389PubMedCrossRef

Tang Y, Gilbert DL, Glauser TA, Hershey AD, Sharp FR. Blood gene expression profiling of neurologic diseases: A pilot microarray study. Arch Neurol. 2005;62:210–215PubMedCrossRef

Tang Y, Lu A, Aronow BJ, Sharp FR. Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: Blood genomic fingerprints of disease. Ann Neurol. 2001;50:699–707PubMedCrossRef

Tang Y, Nee AC, Lu A, Ran R, Sharp FR. Blood genomic expression profile for neuronal injury. J Cereb Blood Flow Metab. 2003;23:310–319PubMedCrossRef

Tang Y, Lu A, Aronow BJ, Wagner KR, Sharp FR. Genomic responses of the brain to ischemic stroke, intracerebral haemorrhage, kainate seizures, hypoglycemia, and hypoxia. Eur J Neurosci. 2002;15:1937–1952PubMedCrossRef

10.

Du X, Tang Y, Xu H, Lit L, Walker W, Ashwood P, Gregg JP, Sharp FR. Genomic profiles for human peripheral blood t cells, b cells, natural killer cells, monocytes, and polymorphonuclear cells: Comparisons to ischemic stroke, migraine, and tourette syndrome. Genomics. 2006;87:693–703PubMedCrossRef

11.

Hallenbeck JM, Hansson GK, Becker KJ. Immunology of ischemic vascular disease: Plaque to attack. Trends Immunol. 2005;26:550–556PubMedCrossRef

12.

Vasan RS. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation. 2006;113:2335–2362PubMedCrossRef

13.

Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to n-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49:1752–1762PubMedCrossRef

14.

Dambinova SA, Khounteev GA, Skoromets AA. Multiple panel of biomarkers for tia/stroke evaluation. Stroke. 2002;33:1181–1182PubMedCrossRef

15.

Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR. Paraneoplastic anti-n-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36PubMedCrossRef

16.

DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the nr2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001;7:1189–1193PubMedCrossRef

17.

Ganor Y, Goldberg-Stern H, Lerman-Sagie T, Teichberg VI, Levite M. Autoimmune epilepsy: Distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/ampa receptor glur3, glutamate/nmda receptor subunit nr2a or double-stranded DNA. Epilepsy Res. 2005;65:11–22PubMedCrossRef

18.

Husebye ES, Sthoeger ZM, Dayan M, Zinger H, Elbirt D, Levite M, Mozes E. Autoantibodies to a nr2a peptide of the glutamate/nmda receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1210–1213PubMedCrossRef

19.

Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke. 2004;35:57–63PubMedCrossRef

20.

Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, Laskowitz DT, Valkirs GE, Buechler KF. Early biomarkers of stroke. Clin Chem. 2003;49:1733–1739PubMedCrossRef

21.

Kim MH, Kang SY, Kim MC, Lee WI. Plasma biomarkers in the diagnosis of acute ischemic stroke. Ann Clin Lab Sci. 2010;40:336–341PubMed

22.

Foerch C, Curdt I, Yan B, Dvorak F, Hermans M, Berkefeld J, Raabe A, Neumann-Haefelin T, Steinmetz H, Sitzer M. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry. 2006;77:181–184PubMedCrossRef

23.

Allard L, Lescuyer P, Burgess J, Leung KY, Ward M, Walter N, Burkhard PR, Corthals G, Hochstrasser DF, Sanchez JC. Apoc-i and apoc-iii as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics. 2004;4:2242–2251PubMedCrossRef

24.

Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: The biomarker rapid assessment in ischemic injury (brain) study. Stroke. 2009;40:77–85PubMedCrossRef

25.

Whiteley W, Lowe G, Rumley N. Blood markers and the diagnosis of stroke or transient attack in the emergency department: A prospective cohort study. J Neurol Neurosurg Psychiatry. 2010;81:e28–29CrossRef

26.

Moore DF, Li H, Jeffries N, Wright V, Cooper RA, Jr., Elkahloun A, Gelderman MP, Zudaire E, Blevins G, Yu H, Goldin E, Baird AE. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: A pilot investigation. Circulation. 2005;111:212–221PubMedCrossRef

27.

Tang Y, Xu H, Du X, Lit L, Walker W, Lu A, Ran R, Gregg JP, Reilly M, Pancioli A, Khoury JC, Sauerbeck LR, Carrozzella JA, Spilker J, Clark J, Wagner KR, Jauch EC, Chang DJ, Verro P, Broderick JP, Sharp FR. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: A microarray study. J Cereb Blood Flow Metab. 2006;26:1089–1102PubMedCrossRef

28.

Barr TL, Conley Y, Ding J, Dillman A, Warach S, Singleton A, Matarin M. Genomic biomarkers and cellular pathways of ischemic stroke by rna gene expression profiling. Neurology. 2010;75:1009–1014PubMedCrossRef

29.

Stamova B, Xu H, Jickling G, Bushnell C, Tian Y, Ander BP, Zhan X, Liu D, Turner R, Adamczyk P, Khoury JC, Pancioli A, Jauch E, Broderick JP, Sharp FR. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke. 2010;41:2171–2177PubMedCrossRef

30.

Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, Jeyaseelan K. Expression profile of micrornas in young stroke patients. PLoS One. 2009;4:e7689PubMedCrossRef

31.

Jin G, Zhou X, Wang H, Wong S. The challenges in blood proteomic biomarker discovery. . New York: Springer 2010.

32.

Sideso E, Papadakis M, Wright C, Handa A, Buchan A, Kessler B, Kennedy J. Assessing the quality and reproducibility of a proteomic platform for clinical stroke biomarker discovery. Translational Stroke Research. 2010;1:304–314CrossRef

33.

Dayon L, Turck N, Garci-Berrocoso T, Walter N, Burkhard PR, Vilalta A, Sahuquillo J, Montaner J, Sanchez JC. Brain extracellular fluid protein changes in acute stroke patients. J Proteome Res. 2011;10:1043–1051PubMedCrossRef

34.

Cuadrado E, Rosell A, Colome N, Hernandez-Guillamon M, Garcia-Berrocoso T, Ribo M, Alcazar A, Ortega-Aznar A, Salinas M, Canals F, Montaner J. The proteome of human brain after ischemic stroke. J Neuropathol Exp Neurol. 2010;69:1105–1115PubMedCrossRef

35.

Montaner J, Perea-Gainza M, Delgado P, Ribo M, Chacon P, Rosell A, Quintana M, Palacios ME, Molina CA, Alvarez-Sabin J. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke. 2008;39:2280–2287PubMedCrossRef

36.

Ageno W, Finazzi S, Steidl L, Biotti MG, Mera V, Melzi D’Eril G, Venco A. Plasma measurement of d-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med. 2002;162:2589–2593PubMedCrossRef

37.

Tombul T, Atbas C, Anlar O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J Clin Neurosci. 2005;12:429–434PubMedCrossRef

38.

Isenegger J, Meier N, Lammle B, Alberio L, Fischer U, Nedeltchev K, Gralla J, Kohler HP, Mattle HP, Arnold M. D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis. 2010;29:82–86PubMedCrossRef

39.

Nakagawa K, Yamaguchi T, Seida M, Yamada S, Imae S, Tanaka Y, Yamamoto K, Ohno K. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis. 2005;19:157–164PubMedCrossRef

40.

Shimizu H, Murakami Y, Inoue S, Ohta Y, Nakamura K, Katoh H, Sakne T, Takahashi N, Ohata S, Sugamori T, Ishibashi Y, Shimada T. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke. 2002;33:1005–1010PubMedCrossRef

41.

Xu H, Tang Y, Liu DZ, Ran R, Ander BP, Apperson M, Liu XS, Khoury JC, Gregg JP, Pancioli A, Jauch EC, Wagner KR, Verro P, Broderick JP, Sharp FR. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: Biomarkers for the etiology of ischemic stroke. J Cereb Blood Flow Metab. 2008;28:1320–1328PubMedCrossRef

42.

Jickling GC, Xu H, Stamova B, Ander BP, Zhan X, Tian Y, Liu D, Turner RJ, Mesias M, Verro P, Khoury J, Jauch EC, Pancioli A, Broderick JP, Sharp FR. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol. 2010;68:681–692PubMedCrossRef

43.

Suwanwela NC, Chutinet A, Phanthumchinda K. Inflammatory markers and conventional atherosclerotic risk factors in acute ischemic stroke: Comparative study between vascular disease subtypes. J Med Assoc Thai. 2006;89:2021–2027PubMed

44.

Hassan A, Hunt BJ, O’Sullivan M, Bell R, D’Souza R, Jeffery S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004;127:212–219PubMedCrossRef

45.

Hassan A, Hunt BJ, O’Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM, Thomas DJ, Markus HS. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain. 2003;126:424–432PubMedCrossRef

46.

Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: Longitudinal results of the austrian stroke prevention study. Stroke. 2005;36:1410–1414PubMedCrossRef

47.

Xu H, Stamova B, Jickling G, Tian Y, Zhan X, Ander BP, Liu D, Turner R, Rosand J, Goldstein LB, Furie KL, Verro P, Johnston SC, Sharp FR, Decarli CS. Distinctive rna expression profiles in blood associated with white matter hyperintensities in brain. Stroke. 2010;41:2744–2749PubMedCrossRef

48.

Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 1997;28:1956–1960PubMedCrossRef

49.

Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of serum s100b as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol. 2005;62:1130–1134PubMedCrossRef

50.

Wunderlich MT, Wallesch CW, Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci. 2004;227:49–53PubMedCrossRef

51.

Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg. 2006;108:558–563PubMedCrossRef

52.

Castillo J, Davalos A, Naveiro J, Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke. 1996;27:1060–1065PubMedCrossRef

53.

Sotgiu S, Zanda B, Marchetti B, Fois ML, Arru G, Pes GM, Salaris FS, Arru A, Pirisi A, Rosati G. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol. 2006;13:505–513PubMedCrossRef

54.

Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325–2329PubMedCrossRef

55.

Montaner J, Rovira A, Molina CA, Arenillas JF, Ribo M, Chacon P, Monasterio J, Alvarez-Sabin J. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab. 2003;23:1403–1407PubMedCrossRef

56.

Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I, Penalba A, Molina CA, Montaner J. A matrix metalloproteinase protein array reveals a strong relation between mmp-9 and mmp-13 with diffusion-weighted image lesion increase in human stroke. Stroke. 2005;36:1415–1420PubMedCrossRef

57.

Shenhar-Tsarfaty S, Ben Assayag E, Bova I, Shopin L, Fried M, Berliner S, Shapira I, Bornstein NM. Interleukin-6 as an early predictor for one-year survival following an ischaemic stroke/transient ischaemic attack. Int J Stroke. 2010;5:16–20PubMedCrossRef

58.

Whiteley W, Rumley A, Sattar N. Blood markers and poor outcome after acute erbrovascular disease: A prospective cohort sutdy. J Neurol Neurosurg Psychiatry. 2010;2010

59.

Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. Lipoprotein-associated phospholipase a2 activity and risk of recurrent stroke. Cerebrovasc Dis. 2009;27:42–50PubMedCrossRef

60.

Gorelick PB. Lipoprotein-associated phospholipase a2 and risk of stroke. Am J Cardiol. 2008;101:34F–40FPubMedCrossRef

61.

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase a(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–1544PubMedCrossRef

62.

Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E. Lipoprotein-associated phospholipase a2, high-sensitivity c-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (aric) study. Arch Intern Med. 2005;165:2479–2484PubMedCrossRef

63.

Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase a2 activity is associated with risk of coronary heart disease and ischemic stroke: The rotterdam study. Circulation. 2005;111:570–575PubMedCrossRef

64.

Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ. Effect of estrogen plus progestin on stroke in postmenopausal women: The women’s health initiative: A randomized trial. JAMA. 2003;289:2673–2684PubMedCrossRef

65.

Castellanos M, Sobrino T, Pedraza S, Moldes O, Pumar JM, Silva Y, Serena J, Garcia-Gil M, Castillo J, Davalos A. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology. 2008;71:1862–1868PubMedCrossRef

66.

Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Davalos A. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke. 2005;36:1921–1926PubMedCrossRef

67.

Castillo J, Davalos A, Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet. 1997;349:79–83PubMedCrossRef

68.

Davalos A, Castillo J, Serena J, Noya M. Duration of glutamate release after acute ischemic stroke. Stroke. 1997;28:708–710PubMedCrossRef

69.

Davalos A, Castillo J, Marrugat J, Fernandez-Real JM, Armengou A, Cacabelos P, Rama R. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology. 2000;54:1568–1574PubMed

70.

Castillo J, Rama R, Davalos A. Nitric oxide-related brain damage in acute ischemic stroke. Stroke. 2000;31:852–857PubMedCrossRef

71.

Serena J, Leira R, Castillo J, Pumar JM, Castellanos M, Davalos A. Neurological deterioration in acute lacunar infarctions: The role of excitatory and inhibitory neurotransmitters. Stroke. 2001;32:1154–1161PubMedCrossRef

72.

Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A. Inflammation-mediated damage in progressing lacunar infarctions: A potential therapeutic target. Stroke. 2002;33:982–987PubMedCrossRef

73.

Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard JP, Boutron C, Couvreur G, Rouanet F, Touze E, Guillon B, Carpentier A, Yelnik A, George B, Payen D, Bousser MG. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (decimal trial). Stroke. 2007;38:2506–2517PubMedCrossRef

74.

Foerch C, Otto B, Singer OC, Neumann-Haefelin T, Yan B, Berkefeld J, Steinmetz H, Sitzer M. Serum s100b predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke. 2004;35:2160–2164PubMedCrossRef

75.

Montaner J. Blood biomarkers to guide stroke thrombolysis. Front Biosci (Elite Ed). 2009;1:200–208

76.

Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998;18:1163–1172PubMedCrossRef

77.

Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003;34:40–46PubMedCrossRef

78.

Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke: Temporal profile and relation to neurological impairment. Stroke. 2001;32:1759–1766PubMedCrossRef

79.

Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke. 2001;32:2762–2767PubMedCrossRef

80.

Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598–603PubMedCrossRef

81.

Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30:34–39PubMedCrossRef

82.

Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, El-Zammar Z, Alam S, Hallenbeck JM, Kidwell CS, Warach S. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke. 2010;41:e123-128PubMedCrossRef

83.

Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004;35:1671–1676PubMedCrossRef

84.

Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, Alvarez-Sabin J. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004;35:2123–2127PubMedCrossRef

85.

Foerch C, Wunderlich MT, Dvorak F, Humpich M, Kahles T, Goertler M, Alvarez-Sabin J, Wallesch CW, Molina CA, Steinmetz H, Sitzer M, Montaner J. Elevated serum s100b levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke. 2007;38:2491–2495PubMedCrossRef

86.

Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost. 2004;91:1146–1151PubMed

87.

Marti-Fabregas J, Borrell M, Cocho D, Belvis R, Castellanos M, Montaner J, Pagonabarraga J, Aleu A, Molina-Porcel L, Diaz-Manera J, Bravo Y, Alvarez-Sabin J, Davalos A, Fontcuberta J, Marti-Vilalta JL. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-pa. Neurology. 2005;65:366–370PubMedCrossRef

88.

Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med. 2009;3:363–383PubMedCrossRef

89.

Serebruany V, Sani Y, Eisert C, Schevchuck A, Fong A, Hanley D. Effects of aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The aggrenox versus aspirin therapy evaluation (agate) biomarker substudy. Thromb Haemost. 2011;105:81–87PubMedCrossRef

90.

Rafferty M, Walters MR, Dawson J. Anti-platelet therapy and aspirin resistance - clinically and chemically relevant? Curr Med Chem. 2010;17:4578–4586PubMedCrossRef

91.

Dobaczewski M, Nocun M, Zavodnik I, Ulicna O, Lapshina E, Zavodnik L, Golanski J, Kazmierczak P, Durackova Z, Kostka B, Markuszewski L, Watala C. Targeting the urine and plasma determinants of thromboxane a2 metabolism in detection of aspirin effectiveness. Blood Coagul Fibrinolysis. 2008;19:421–428PubMedCrossRef

92.

Harrison P. The role of pfa-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005;130:3–10PubMedCrossRef

93.

Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke. 2005;36:1001–1005PubMedCrossRef

94.

Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702–1708PubMedCrossRef

95.

Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of cyp2c19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704–1714PubMedCrossRef

96.

Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.

97.

Weinstein PR, Hong S, Sharp FR. Molecular identification of the ischemic penumbra. Stroke. 2004;35:2666–2670PubMedCrossRef

98.

Castellanos M, Sobrino T, Castillo J. Evolving paradigms for neuroprotection: Molecular identification of ischemic penumbra. Cerebrovasc Dis. 2006;21 Suppl 2:71–79PubMedCrossRef

99.

Frykholm P, Hillered L, Langstrom B, Persson L, Valtysson J, Enblad P. Relationship between cerebral blood flow and oxygen metabolism, and extracellular glucose and lactate concentrations during middle cerebral artery occlusion and reperfusion: A microdialysis and positron emission tomography study in nonhuman primates. J Neurosurg. 2005;102:1076–1084PubMedCrossRef

100.

Sharp FR, Lu A, Tang Y, Millhorn DE. Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab. 2000;20:1011–1032PubMedCrossRef

101.

Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR. Induction of hypoxia-inducible factor-1 (hif-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci. 1999;11:4159–4170PubMedCrossRef

102.

Hill MD, Jackowski G, Bayer N, Lawrence M, Jaeschke R. Biochemical markers in acute ischemic stroke. CMAJ. 2000;162:1139–1140PubMed

103.

Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR. Association of serial biochemical markers with acute ischemic stroke: The national institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke study. Stroke. 2006;37:2508–2513PubMedCrossRef

104.

Lamers KJ, Vos P, Verbeek MM, Rosmalen F, van Geel WJ, van Engelen BG. Protein s-100b, neuron-specific enolase (nse), myelin basic protein (mbp) and glial fibrillary acidic protein (gfap) in cerebrospinal fluid (csf) and blood of neurological patients. Brain Res Bull. 2003;61:261–264PubMedCrossRef

105.

Verma S, Yeh ET. C-reactive protein and atherothrombosis--beyond a biomarker: An actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1253–1256; discussion R1257–1258PubMed

106.

Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D. Evaluation of c-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the crp pooling project members. Stroke. 2005;36:1316–1329PubMedCrossRef

107.

Arenillas JF, Alvarez-Sabin J, Molina CA, Chacon P, Montaner J, Rovira A, Ibarra B, Quintana M. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke. 2003;34:2463–2468PubMedCrossRef

108.

Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, Tracy RP. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107:2016–2020PubMedCrossRef

109.

Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D’Agostino RB, Franzblau C, Wilson PW. Plasma concentration of c-reactive protein and risk of ischemic stroke and transient ischemic attack: The framingham study. Stroke. 2001;32:2575–2579PubMedCrossRef

110.

Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, del Zoppo GJ, Hallenbeck JM, Rothwell NJ, Hopkins SJ, Tyrrell PJ. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004;4:2PubMedCrossRef

111.

Wassertheil-Smoller S, Kooperberg C, McGinn AP, Kaplan RC, Hsia J, Hendrix SL, Manson JE, Berger JS, Kuller LH, Allison MA, Baird AE. Lipoprotein-associated phospholipase a2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension. 2008;51:1115–1122PubMedCrossRef

112.

Di Napoli M, Papa F, Bocola V. Prognostic influence of increased c-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32:133–138PubMedCrossRef

113.

Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med. 1993;118:956–963PubMed

114.

Mauriello A, Sangiorgi G, Palmieri G, Virmani R, Holmes DR, Jr., Schwartz RS, Pistolese R, Ippoliti A, Spagnoli LG. Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. Circulation. 2000;101:744–750PubMed

115.

Fon EA, Mackey A, Cote R, Wolfson C, McIlraith DM, Leclerc J, Bourque F. Hemostatic markers in acute transient ischemic attacks. Stroke. 1994;25:282–286PubMedCrossRef

116.

Rainer TH, Wong LK, Lam W, Yuen E, Lam NY, Metreweli C, Lo YM. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem. 2003;49:562–569PubMedCrossRef

117.

Allard L, Burkhard PR, Lescuyer P, Burgess JA, Walter N, Hochstrasser DF, Sanchez JC. Park7 and nucleoside diphosphate kinase a as plasma markers for the early diagnosis of stroke. Clin Chem. 2005;51:2043–2051PubMedCrossRef

Titel: Blood Biomarkers of Ischemic Stroke
verfasst von: Glen C. Jickling
Frank R. Sharp
Publikationsdatum: 01.07.2011
Verlag: Springer-Verlag
Erschienen in: Neurotherapeutics / Ausgabe 3/2011
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-011-0050-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Blood Biomarkers of Ischemic Stroke

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Antiplatelet Agents for Stroke Prevention

Introduction

Stroke Prevention-Surgical and Interventional Approaches to Carotid Stenosis

Investigational Therapies for Ischemic Stroke: Neuroprotection and Neurorecovery

Prevention of Cardioembolic Stroke

Treatment of Risk Factors to Prevent Stroke

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie